624734-19-6Relevant articles and documents
SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
-
, (2016/05/02)
Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
-
Page/Page column 86; 87, (2014/10/03)
The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
SERINE/THREONINE KINASE INHIBITORS
-
Paragraph 0245-0246, (2014/03/25)
Compounds having the formula I wherein R2, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
CHEMOKING RECEPTOR ANTAGONISTS
-
, (2013/03/26)
Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS
-
Paragraph 00220, (2013/03/26)
Compounds having the formula (I) wherein R1, R2, R3 and Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
SERINE/THREONINE KINASE INHIBITORS
-
Paragraph 00254, (2013/09/12)
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Enantioselective organocatalytic α-fluorination of cyclic ketones
Kwiatkowski, Piotr,Beeson, Teresa D.,Conrad, Jay C.,MacMillan, David W. C.
supporting information; body text, p. 1738 - 1741 (2011/04/17)
The first highly enantioselective α-fluorination of ketones using organocatalysis has been accomplished. The long-standing problem of enantioselective ketone α-fluorination via enamine activation has been overcome via high-throughput evaluation of a new library of amine catalysts. The optimal system, a primary amine functionalized Cinchona alkaloid, allows the direct and asymmetric α-fluorination of a variety of carbo- and heterocyclic substrates. Furthermore, this protocol also provides diastereo-, regio-, and chemoselective catalyst control in fluorinations involving complex carbonyl systems.
NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS
-
Page/Page column 94, (2011/12/02)
The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of formula (I) wherein HET is a group selected from among formulas (IIa) (IIb) (IIc) (IId) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD and pain diseases.
NEW CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS
-
Page/Page column 75-76, (2011/12/02)
The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD and pain diseases
Design, synthesis, and structure-activity relationship of novel CCR2 antagonists
Kothandaraman, Shankaran,Donnely, Karla L.,Butora, Gabor,Jiao, Richard,Pasternak, Alexander,Morriello, Gregori J.,Goble, Stephen D.,Zhou, Changyou,Mills, Sander G.,MacCoss, Malcolm,Vicario, Pasquale P.,Ayala, Julia M.,DeMartino, Julie A.,Struthers, Mary,Cascieri, Margaret A.,Yang, Lihu
scheme or table, p. 1830 - 1834 (2009/11/30)
A series of novel 1-aminocyclopentyl-3-carboxyamides incorporating substituted tetrahydropyran moieties have been synthesized and subsequently evaluated for their antagonistic activity against the human CCR2 receptor. Among them analog 59 was found to posses potent antagonistic activity.